Floatz logo

Liraglutide

Binge Eating Behaviour

Universiti Kebangsaan Malaysia Medical Centreprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Binge Eating Behaviour cohort.

Asset / SponsorPhaseRating
Sibutramine
Yale University
Phase 4BBB
Topamax
University of Virginia
Phase 3BB
Namenda
Mclean Hospital
Phase 4BB
Orlistat
Yale University
Phase 4BB
Armodafinil
Lindner Center of HOPE
Phase 3BB

View all 12 →

Same molecule, other indications

Liraglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
84 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →